文献速递胸部肿瘤放疗放疗物理与技术

碳离子放疗后放射性肺炎的预后分析:局部晚期肺癌患者

Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer.
PubMed 文献 · Radiat Oncol · 2017-05-30

该研究回顾性分析65例接受碳离子放疗的局部晚期非小细胞肺癌患者,≥2级放射性肺炎发生率为9%,3级为5%。多因素分析显示%VC<86.9%和V30≥15%是≥2级放射性肺炎的显著危险因素。

要点

  • ≥2级放射性肺炎发生率为9%,3级为5%,未观察到4级或5级放射性肺炎。
  • %VC<86.9%和V30≥15%是碳离子放疗后≥2级放射性肺炎的独立危险因素。
  • 单因素分析中MLD、V5、V10、V20、V30等剂量学参数与≥2级放射性肺炎显著相关。

核心结论

  • 碳离子放疗后≥2级放射性肺炎的独立危险因素为%VC<86.9%和V30≥15%。

研究设计与样本

  • 回顾性分析2000至2015年间在国家放射科学研究所接受碳离子放疗的65例非小细胞肺癌患者。
  • 临床分期IIB期最常见(45%),中位放疗剂量72 Gy(RBE)(范围68-76 Gy),分16次。
  • 淋巴结转移者预防性照射纵隔淋巴结,中位剂量49.5 Gy(RBE),中位随访22个月。

主要发现

  • 2级和3级放射性肺炎分别发生6例和3例(9%和5%),无4级或5级放射性肺炎。
  • 单因素分析显示%VC、FEV1、MLD、V5、V10、V20和V30是≥2级放射性肺炎的显著预测因素。
  • ROC分析确定%VC、FEV1、MLD、V5、V10、V20和V30的截断值分别为86.9%、1.16 L、12.5 Gy(RBE)、28.8%、29.9%、20.1%和15.0%。
  • 多因素分析显示%VC<86.9%(OR=13.7;p=0.0041)和V30≥15%(OR=6.1;p=0.0221)是显著危险因素。

关键数值与推荐

  • ≥2级放射性肺炎的ROC截断值:%VC 86.9%,FEV1 1.16 L,MLD 12.5 Gy(RBE),V5 28.8%,V10 29.9%,V20 20.1%,V30 15.0%。
  • 多因素分析中%VC<86.9%的OR=13.7(p=0.0041),V30≥15%的OR=6.1(p=0.0221)。

临床怎么用

  • 碳离子放疗前应评估患者%VC和FEV1等肺功能指标。
  • 计划设计时关注MLD及V5、V10、V20、V30等剂量学参数,尤其V30应尽量低于15%。

局限性

  • 回顾性研究,样本量65例,来自单中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carbon-ion radiotherapy (CIRT) is a promising treatment for locally advanced non-small-cell lung cancer, especially for patients with inoperable lung cancer. Although the incidence of CIRT-induced radiation pneumonitis (RP) ≥ grade 2 ranges from 2.5 to 9.9%, the association between CIRT-induced RP and dosimetric parameters is not clear. Herein, we identified prognostic factors associated with symptomatic RP after CIRT for patients with non-small-cell lung cancer. METHODS: Clinical results of 65 patients treated with CIRT between 2000 and 2015 at the National Institute of Radiological Sciences were retrospectively analyzed. Clinical stage II B disease (TNM classification) was the most common stage among the patients (45%). The median radiation dose was 72 Gy (68-76) relative biological effectiveness (RBE) in 16 fractions. In cases involving metastatic lymph nodes, prophylactic irradiation of mediastinal lymph nodes was performed at a median dose of 49.5 Gy (RBE). The median follow-up was 22 months. RESULTS: Grade 2 and grade 3 RP occurred in 6 and 3 patients (9 and 5%), respectively. No patients developed grade 4 or 5 RP. Using univariate analysis, vital capacity as a percentage of predicted (%VC), forced expiratory volume in 1 s (FEV1), mean lung dose (MLD), volume of lung receiving ≥5 Gy (RBE) (V5), V10, V20 and V30 were determined to be the significant predictive factors for ≥ grade 2 RP. The receiver operating characteristic (ROC) analysis revealed the cutoff values for %VC, FEV1, MLD, V5, V10, V20 and V30 for ≥ grade 2 RP, which were 86.9%, 1.16 L, 12.5 Gy (RBE), 28.8, 29.9, 20.1 and 15.0%, respectively. In addition, the multivariate analysis revealed that %VC <86.9% (odds ratio = 13.7; p = 0.0041) and V30 ≥ 15% (odds ratio = 6.1; p = 0.0221) were significant risk factors. CONCLUSIONS: Our study demonstrated the risk factors for ≥ grade 2 RP after carbon-ion radiotherapy for patients with locally advanced lung cancer.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Hayashi K, Yamamoto N, Karube M, et al. Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer. Radiat Oncol. 2017. PMID: 28558766. doi:10.1186/s13014-017-0830-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。